Enter assignee name

EPO Patents = 4

Forward Citations = 88

Loading Chart...

6 inventors (with patents filed for the assignee):

Xicheng David Sun (17 out of 49 patents)

Jian Qiu (15 out of 38 patents)

Jan William Wasley (9 out of 30 patents)

4. Sarah A Strong (7 out of 24 patents)

5. Gary Joseph Rosenthal (7 out of 18 patents)

6. Adam Stout (2 out of 10 patents)

17 patents: Sort by Forward Citations

1. 8957105 - Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents (2015-02-17),

2. 8946434 - Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists (2015-02-03),

3. 8921562 - Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors (2014-12-30),

4. 8906933 - Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists (2014-12-09),

5. 8859611 - Thiophene inhibitors of S-nitrosoglutathione reductase (2014-10-14),

6. 8846736 - Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents (2014-09-30),

7. 8785643 - Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors (2014-07-22),

8. 8759548 - S-nitrosoglutathione reductase inhibitors (2014-06-24),

9. 8741915 - Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors (2014-06-03),

10. 8691816 - Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents (2014-04-08),

11. 8686015 - Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents (2014-04-01),

12. 8673961 - Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents (2014-03-18),

13. 8669381 - Chromone inhibitors of S-nitrosoglutathione reductase (2014-03-11),

14. 8642628 - Pyrrole inhibitors of S-nitrosoglutathione reductase (2014-02-04),

15. 8586624 - Thiophene inhibitors of S-nitrosoglutathione reductase (2013-11-19),

N30 Pharmaceuticals, Inc. is a biopharmaceutical company committed to discovering and developing innovative treatments for respiratory diseases. Our focus lies in creating therapies that target key inflammatory pathways to significantly improve patients' lives. With a dedicated team and state-of-the-art research facilities, we aim to revolutionize the field of respiratory medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

17 Patents

#71 in Boulder, CO

#366 in Colorado

#18,344 in US

#34,877 in the World

Boulder, CO, United States of America

N30 Pharmaceuticals, Inc.